TrialBlood advances2023

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Anne-Sophie Michallet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.